We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

313 hedge funds and large institutions have $7.38B invested in Immunomedics Inc in 2020 Q2 according to their latest regulatory filings, with 117 funds opening new positions, 91 increasing their positions, 81 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

432% more first-time investments, than exits

New positions opened: 117 | Existing positions closed: 22

203% more capital invested

Capital invested by funds: $2.44B → $7.38B (+$4.94B)

175% more call options, than puts

Call options by funds: $181M | Put options by funds: $66M

129% more funds holding in top 10

Funds holding in top 10: 716 (+9)

42% more funds holding

Funds holding: 220313 (+93)

12% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 81

Holders
313
Holders Change
+93
Holders Change %
+42.27%
% of All Funds
6.42%
Holding in Top 10
16
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+128.57%
% of All Funds
0.33%
New
117
Increased
91
Reduced
81
Closed
22
Calls
$181M
Puts
$66M
Net Calls
+$115M
Net Calls Change
+$103M
Name Holding Trade Value Shares
Change
Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$930M +$51.2M +1,750,000 +7%
Vanguard Group
2
Vanguard Group
Pennsylvania
$669M +$58.9M +2,014,353 +12%
BlackRock
3
BlackRock
New York
$500M -$48.6M -1,663,667 -11%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$411M +$215M +7,360,258 +174%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$244M +$57M +1,950,783 +40%
BC
6
Boxer Capital
California
$234M -$53.9M -1,844,000 -22%
PAI
7
Palo Alto Investors
California
$184M -$3.15M -107,763 -2%
Alkeon Capital Management
8
Alkeon Capital Management
New York
$164M +$43.9M +1,500,000 +48%
RM
9
RP Management
New York
$155M
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$154M +$25.1M +858,690 +25%
State Street
11
State Street
Massachusetts
$151M -$82M -2,806,049 -40%
RG
12
Redmile Group
California
$124M +$102M +3,489,900 New
ACH
13
ArrowMark Colorado Holdings
Colorado
$120M -$54.2M -1,855,146 -35%
Lord, Abbett & Co
14
Lord, Abbett & Co
New Jersey
$117M +$96.7M +3,306,343 New
PHS
15
PFM Health Sciences
California
$113M +$61.8M +2,114,933 +199%
Goldman Sachs
16
Goldman Sachs
New York
$112M +$61.8M +2,114,365 +201%
Jennison Associates
17
Jennison Associates
New York
$110M -$56M -1,914,054 -38%
Ameriprise
18
Ameriprise
Minnesota
$110M -$61.6M -2,106,351 -41%
Franklin Resources
19
Franklin Resources
California
$106M +$19M +651,500 +36%
American Century Companies
20
American Century Companies
Missouri
$98M +$3.57M +121,973 +5%
Fiera Capital (Canada)
21
Fiera Capital (Canada)
Quebec, Canada
$95.3M -$1.61M -54,939 -2%
MWNA
22
Marshall Wace North America
New York
$92.2M +$60.8M +2,079,733 +399%
DM
23
Deerfield Management
New York
$90.8M -$45.2M -1,546,464 -38%
Geode Capital Management
24
Geode Capital Management
Massachusetts
$88.7M -$7.92M -271,053 -10%
PAMU
25
Pictet Asset Management (UK)
United Kingdom
$83.5M +$28.5M +973,520 +70%

IMMU Hedge Fund Activity: Q2 2020 in Review

313 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q2 2020, worth a combined $7.38B — up 203% from $2.44B a quarter earlier.

Buyers outnumbered sellers: 117 funds opened new IMMU positions and 22 closed out — a net gain of 95 holders — while 91 added to existing stakes and 81 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $215M. The largest seller was Victory Capital Management, cutting an estimated $82.4M.

  • 313 institutional investors held Immunomedics Inc (IMMU) as of Q2 2020, up from 220 in Q1 2020.
  • Funds reported $7.38B of Immunomedics Inc stock for Q2 2020, up 203% quarter-over-quarter.
  • 117 funds opened new Immunomedics Inc positions in Q2 2020 and 22 closed out, a net change of +95 holders.
  • The largest Immunomedics Inc buyer in Q2 2020 was Fidelity Investments, an estimated $215M added.
  • The largest Immunomedics Inc seller in Q2 2020 was Victory Capital Management, an estimated $82.4M sold.

Based on aggregated 13F filings for Q2 2020.